By Nell Mackenzie and Samuel Indyk LONDON, Feb 13 (Reuters) - Hedge fund bets against Hims & Hers Health hit their highest in ...

Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted. Click to read more on HIMS stock.

Downgrade Hims & Hers Health, Inc. to Hold as FDA scrutiny and Novo’s lawsuit threaten compounded GLP-1 revenue. Click for ...

What Happened? A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price ...

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA ...

Narrated by Common, Hims & Hers' 2026 Super Bowl ad positions affordability as part of the solution to the income disparities shaping health outcomes.

NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health will begin offering copies of Novo Nordisk's new Wegovy pill at an introductory price of $49 per month, the company said ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.5, a high estimate of $60.00 ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Hims & Hers Health, Inc. (HIMS) reports results for the quarter ended September 2025. While this widely-known ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 13 unusual trades. Delving into the details, we ...

Hers specializes in women's healthcare, connecting users to virtual consultations for various health concerns, including weight loss. Explore personalized weight loss plans incorporating nutrition ...